Matches in DBpedia 2016-04 for { ?s ?p "Mapatumumab (HGS-ETR1) is an experimental human monoclonal antibody undergoing clinical trials for the treatment of cancer.This drug was discovered by Cambridge Antibody Technology (CAT) and Human Genome Sciences, Inc. (HGS) as a result of the collaboration between the two companies in 1999 in exploitation CAT's phage display technology.Early work by CAT and HGS indicated that mapatumumab induced cell death in multiple tumour types both in vitro and in vivo."@en }
Showing triples 1 to 4 of
4
with 100 triples per page.
- Mapatumumab abstract "Mapatumumab (HGS-ETR1) is an experimental human monoclonal antibody undergoing clinical trials for the treatment of cancer.This drug was discovered by Cambridge Antibody Technology (CAT) and Human Genome Sciences, Inc. (HGS) as a result of the collaboration between the two companies in 1999 in exploitation CAT's phage display technology.Early work by CAT and HGS indicated that mapatumumab induced cell death in multiple tumour types both in vitro and in vivo.".
- Q6753781 abstract "Mapatumumab (HGS-ETR1) is an experimental human monoclonal antibody undergoing clinical trials for the treatment of cancer.This drug was discovered by Cambridge Antibody Technology (CAT) and Human Genome Sciences, Inc. (HGS) as a result of the collaboration between the two companies in 1999 in exploitation CAT's phage display technology.Early work by CAT and HGS indicated that mapatumumab induced cell death in multiple tumour types both in vitro and in vivo.".
- Mapatumumab comment "Mapatumumab (HGS-ETR1) is an experimental human monoclonal antibody undergoing clinical trials for the treatment of cancer.This drug was discovered by Cambridge Antibody Technology (CAT) and Human Genome Sciences, Inc. (HGS) as a result of the collaboration between the two companies in 1999 in exploitation CAT's phage display technology.Early work by CAT and HGS indicated that mapatumumab induced cell death in multiple tumour types both in vitro and in vivo.".
- Q6753781 comment "Mapatumumab (HGS-ETR1) is an experimental human monoclonal antibody undergoing clinical trials for the treatment of cancer.This drug was discovered by Cambridge Antibody Technology (CAT) and Human Genome Sciences, Inc. (HGS) as a result of the collaboration between the two companies in 1999 in exploitation CAT's phage display technology.Early work by CAT and HGS indicated that mapatumumab induced cell death in multiple tumour types both in vitro and in vivo.".